Compare AMRX & CHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRX | CHH |
|---|---|---|
| Founded | 2002 | 1939 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.4B |
| IPO Year | 2018 | 1997 |
| Metric | AMRX | CHH |
|---|---|---|
| Price | $12.82 | $101.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 11 |
| Target Price | $15.60 | ★ $114.30 |
| AVG Volume (30 Days) | ★ 1.4M | 566.6K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.98% |
| EPS Growth | ★ 157.89 | 27.42 |
| EPS | 0.22 | ★ 0.44 |
| Revenue | N/A | ★ $1,596,793,000.00 |
| Revenue This Year | $4.48 | $66.74 |
| Revenue Next Year | $7.13 | $0.37 |
| P/E Ratio | $58.41 | ★ $12.62 |
| Revenue Growth | N/A | ★ 0.75 |
| 52 Week Low | $7.02 | $84.04 |
| 52 Week High | $15.42 | $136.45 |
| Indicator | AMRX | CHH |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 37.07 |
| Support Level | $12.45 | $99.40 |
| Resistance Level | $12.85 | $101.98 |
| Average True Range (ATR) | 0.48 | 4.10 |
| MACD | -0.00 | -2.16 |
| Stochastic Oscillator | 29.84 | 9.46 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.